[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07543159":3,"trial-entities:NCT07543159":72,"trial-summary:NCT07543159":76},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":27,"primary_purpose":28,"phases":29,"enrollment_info":30,"interventions":33,"primary_outcomes":34,"secondary_outcomes":39,"sex":40,"minimum_age":41,"maximum_age":28,"healthy_volunteers":42,"eligibility_criteria":43,"std_ages":47,"locations":50,"central_contacts":65,"overall_officials":69,"references":70,"see_also_links":71},"NCT07543159","WCG Protocol #20253750","Clinical Biospecimen Collection","New York Cancer and Blood Specialists: Clinical Biospecimen Collection for Research Use","RECRUITING","2035-10-06","2025-10","2026-04-24","2025-12-23","North Shore Hematology Oncology Associates P.C dba New York Cancer and Blood Specialists","OTHER",false,"New York Cancer and Blood Specialists(NYCBS) is dedicated to provide world-class, patient-centered, affordable care to patients with cancer and blood disorders in their own communities, close to family and friends. Our vision is a world free of cancer and blood disorders by contributing to the search for cures by offering cutting-edge clinical trials and personalized, state-of-the-art treatments that save and prolong lives. In support of these objectives NYCBS has created a centralized oncology biorepository in tandem with a longitudinal study to support translational research. This study establishes a biological sample bank and associated data reservoir from thousands of cancer patients, high risk populations, and survivors. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. Researchers will then use these samples and information to better understand how cancer affects the body over time in order to formulate new treatments. The information and samples provided will allow the testing of new therapies and aid in the development of new medical treatments.","Research and development of new diagnostics for earlier detection of, and new treatments for diseases require the use of human biological specimens (biospecimens). Through data and insight gained from the evaluation of these collected biospecimens, the aforementioned novel diagnostics and\u002For treatments can be developed or validated for a variety of diseases. Biospecimens collected under this protocol may be obtained from subjects with benign conditions, subjects who have been diagnosed with or suspected of having oncological diseases, infectious diseases, auto-immune diseases, endocrine disorders, as well as subjects from healthy normal donors.\n\nThe samples and data may be used for genetic research such as: RNA or DNA isolation and analysis, gene and protein expression, diagnostic device and biomarker research, tissue microarray development, laboratory tests and validation tests. The biospecimens may also be used for genome sequencing.",[19],"Cancer Risk",[21,22,23,24,25,26],"New York Cancer","Oncology","Cancer","Clinical Trial","Biobank","Umbrella","OBSERVATIONAL",null,[],{"count":31,"type":32},900000,"ESTIMATED",[],[35],{"measure":36,"description":37,"timeFrame":38},"Development of Assays, or Novel Diagnostic's and Treatments to Improve the Quality\u002FQuantity of life for diseased individuals.","Expedite development of diagnostic assays and\u002For novel treatments to improve the quality and\u002For quantity of life for diseased individuals. Samples may also be utilized in the development of commercial diagnostic reagents.\" Reagents such as RNA, DNA, and proteins may be involved. Use of this genetic information may aid in the development of novel diagnostics and therapies for patients with certain diseases.","10 years",[],"ALL","18 Years",true,{"inclusion":44,"exclusion":45,"raw_text":46},[],[],"Inclusion Criteria:\n\n1. Subjects must be at least 18 years of age\n2. Subjects must be deemed competent by a qualified clinical study researcher to provide legally documented informed consent\n3. Subjects may or may not have active disease at the time of enrollment\n4. Biospecimens collected under this protocol may be obtained from subjects with benign conditions, subjects who have been diagnosed with or suspected of having oncological diseases, infectious diseases, auto-immune diseases, endocrine disorders, as well as subjects from healthy normal donors.\n\nExclusion Criteria:\n\n4\\) Subjects not meeting the inclusion criteria\n\nAdditional inclusion and exclusion criteria may exist, specific to individual project plans, for each collection falling under this protocol. These criteria may include genetic mutation status, progression of disease, and prior lines of therapy among others.",[48,49],"ADULT","OLDER_ADULT",[51],{"facility":52,"status":8,"city":53,"state":54,"zip":55,"country":56,"contacts":57,"geoPoint":62},"NYCBS","Shirley","New York","11967","United States",[58],{"name":59,"role":60,"email":61},"Andrew Lee, MHA","CONTACT","andrew.lee@nycancer.com",{"lat":63,"lon":64},40.80149,-72.8676,[66],{"name":59,"role":60,"phone":67,"email":68},"16313935767","Biobanking@nycancer.com",[],[],[],{"nct_id":4,"conditions":73,"biomarkers":75},[74],"Malignant Neoplasm",[],{"nct_id":4,"found":42,"summary":77,"prompt_version":87},{"design":78,"status":79,"heading":80,"summary":81,"follow_up":82,"word_count":83,"commitments":84,"compensation":85,"drugs_mentioned":86},"This is an observational study with a planned enrollment of 900,000 participants. It is collecting biological samples and associated data.","completed","Clinical Biospecimen Collection for Cancer Risk Research","This observational study, run by New York Cancer and Blood Specialists (NYCBS), is collecting human biological samples (biospecimens) and health information from a large number of people. The goal is to create a resource that researchers can use to develop new ways to detect diseases earlier and create better treatments for various conditions, including cancer. You can join if you are at least 18 years old and can provide informed consent. You may or may not have an active disease, and samples can come from people with benign (non-cancerous) conditions, those with cancer or other diseases, or healthy individuals. The study aims to develop new diagnostic tools and treatments to improve the quality and length of life for people with diseases, with results expected in 10 years.","The primary goal of developing new diagnostics and treatments is measured at 10 years.",127,"Not specified in the trial record.","Not stated in the trial record.",[],"v2"]